Document Detail


Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).
MedLine Citation:
PMID:  19585059     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Scalp psoriasis occurs in 50%-75% of patients with plaque psoriasis. It may be the only area of the body affected, or it may be associated with disease elsewhere, including psoriatic arthritis. Most cases are treated topically, usually with steroids and/or calcipotriol. In 2008, Health Canada and the US FDA approved a stable, once-daily 2-compound gel containing calcipotriol and betamethasone dipropionate (Xamiol, LEO Pharma; Taclonex Scalp, Warner Chilcott). This once-daily therapy improves patient quality of life with a quick onset of action and greater efficacy than monotherapy with either ingredient or twice daily treatment with calcipotriol 0.005% (Dovonex, LEO Pharma) scalp solution. The gel vehicle was developed for ease of use, improved cosmetic acceptability and absorption on the scalp. By 2 weeks, approximately 60%, and by 8 weeks, approximately 70% of patients have controlled disease (i.e., absent or very mild disease). At 8 weeks, the calcipotriol and betamethasone dipropionate gel formulation has a safety profile comparable with betamethasone dipropionate and is associated with significantly fewer adverse events than calcipotriol. Xamiol may be safely used for up to 52 weeks. No cases of atrophy, striae, or steroid purpura were noted in two 52-week studies.
Authors:
L C Guenther
Related Documents :
20707829 - Infliximab efficacy in nail psoriasis. a retrospective study in 48 patients.
11756949 - Topical tacrolimus (fk506) and mometasone furoate in treatment of dyshidrotic palmar ec...
19681859 - Tolerability of high-dose topical tretinoin: the veterans affairs topical tretinoin che...
15960629 - Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a...
15075889 - Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment in ato...
22387979 - A 5-year retrospective study of survival of zirconia single crowns fitted in a private ...
17138949 - Clinical deterioration after intravenous recombinant tissue plasminogen activator treat...
24322799 - Simultaneous surgery for corneal edema and aphakia: dsek and placement of a retropupill...
17891039 - Young and heavy patients with a cementless tka do as well as older and lightweight pati...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Skin therapy letter     Volume:  14     ISSN:  1201-5989     ISO Abbreviation:  Skin Therapy Lett.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-07-08     Completed Date:  2009-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9891441     Medline TA:  Skin Therapy Lett     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  IM    
Affiliation:
The Guenther Dermatology Research Centre, London, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / therapeutic use*
Betamethasone / analogs & derivatives*,  therapeutic use
Calcitriol / analogs & derivatives*,  therapeutic use
Dermatologic Agents / therapeutic use*
Drug Administration Schedule
Drug Combinations
Gels
Humans
Psoriasis / drug therapy*
Scalp Dermatoses / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Dermatologic Agents; 0/Drug Combinations; 0/Gels; 112965-21-6/calcipotriene; 32222-06-3/Calcitriol; 378-44-9/Betamethasone; 5593-20-4/betamethasone-17,21-dipropionate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatments for pityriasis rosea.
Next Document:  Use of tacrolimus ointment in vitiligo alone or in combination therapy.